Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema.

Purpose: The aim of this study was to assess the effect of intravitreal injections (IVI) of ranibizumab and aflibercept on the choroidal thickness (CT) in patients with treatment-naive diabetic macular edema (DME) before and after monthly IVI. Patients and Methods . Prospective monocenter study. Inclusion criteria were treatment-naive DME eyes without concomitant panretinal photocoagulation, associated with a decrease in best-corrected visual acuity ≤75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. DME was defined by a central retinal thickness ≥300  μ m on swept-source OCT (Triton DRI OCT, Topcon Corporation, Itabashi, Japan). Patients received 5 IVI of ranibizumab or aflibercept. The primary endpoint was the change in the central subfield CT (CSCT) between inclusion (M0) and 1 month after the fifth IVI (M5). The secondary endpoint was the CT changes between M0 and M5 in other locations of the macular ETDRS grid.
Results: Twenty-four eyes of 24 patients with a mean age of 61.1 years were included. Eleven and 13 patients were, respectively, treated with ranibizumab and aflibercept, and 86.4% had type 2 diabetes. The overall CSCT decreased significantly by -12  μ m between M0 and M5 (231.7  μ m at M0 and 219.7  μ m at M5) ( p =0.03). It decreased by -15.2  μ m ( p =0.02) in the aflibercept group (206.9  μ m at M0 and 191.7  μ m at M5) and by -7.3  μ m ( p =0.4) in the ranibizumab group (267.5  μ m at M0 and 260.2  μ m at M5). The CSCT decreased by -4.9  μ m in noninjected contralateral eyes (242.3  μ m at M0 and 237.4  μ m at M5). CT changes between M0 and M5 in the superior, temporal, inferior, and nasal macular inner ring were significant in the aflibercept group but not in the ranibizumab and control groups.
Conclusion: In DME patients, the CSCT decreases after 5 IVI of anti-VEGF, especially after aflibercept treatment.
Competing Interests: V. Sarda, P. Eymard, and L. Hrarat have nothing to disclose. F. Fajnkuchen and A. Giocanti-Aurégan are consultants for Allergan, Bayer, and Novartis. The authors declare no conflicts of interest related to the submitted work.
(Copyright © 2020 Valérie Sarda et al.)